ABSTRACT
Background Blood lipids are dysregulated in pulmonary hypertension (PH). Lower high-density lipoproteins cholesterol (HDL-C) and low-density lipoproteins cholesterol (LDL-C) are associated with disease severity and death in PH. Right ventricle (RV) dysfunction and failure are the major determinants of morbidity and mortality in PH. This study aims to test the hypothesis that dyslipidemia is associated with RV dysfunction in PH.
Methods We enrolled healthy control subjects (n=12) and individuals with PH (n=30) (age: 18-65 years old). Clinical characteristics, echocardiogram, 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (PET) scan, blood lipids, including total cholesterol (TC), triglycerides (TG), lipoproteins (LDL-C and HDL-C), and N-terminal pro-B type Natriuretic Peptide (NT-proBNP) were determined.
Results Individuals with PH had lower HDL-C [PH, 41±12; control, 56±16 mg/dL, p<0.01] and higher TG to HDL-C ratio [PH, 3.6±3.1; control, 2.2±2.2, p<0.01] as compared to controls. TC, TG, and LDL-C were similar between PH and controls. Lower TC and TG were associated with worse RV function measured by RV strain (R=–0.43, p=0.02 and R=–0.37, p=0.05 respectively), RV fractional area change (R=0.51, p<0.01 and R=0.48, p<0.01 respectively), RV end-systolic area (R=–0.63, p<0.001 and R=–0.48, p<0.01 respectively), RV end-diastolic area: R=–0.58, p<0.001 and R=–0.41, p=0.03 respectively), and RV glucose uptake by PET (R=–0.46, p=0.01 and R=–0.30, p=0.10 respectively). NT-proBNP was negatively correlated with TC (R=–0.61, p=0.01) and TG (R=–0.62, p<0.02) in PH.
Conclusion These findings confirm dyslipidemia is associated with worse right ventricular function in PH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by the following grants: R01HL115008 (SCE), R01HL060917 (SCE) and 4UL1TR002548 (CTSC, AM - pilot grant)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved the Cleveland Clinic Foundation Institutional Review Board (#11-1198).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
“This work has not been published previously and it is not under consideration for publication elsewhere. All authors gave approval for this manuscript to be published.”
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
List of Abbreviations
- ApoA-I
- Apolipoprotein A-I
- ASE
- American Society of Echocardiography
- ATS
- American Thoracic Society
- CAMPHOR
- Cambridge Pulmonary Hypertension Outcome Review
- FDG
- 2-[18F] fluoro-2-deoxy-D-glucose
- HDL-C
- High-Density Lipoprotein Cholesterol
- LDL-C
- Low-Density Lipoprotein Cholesterol
- LV
- Left Ventricle
- NT-proBNP
- N-terminal pro-B type Natriuretic Peptide
- NYHA
- New York Heart Association
- PAHTCH
- Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure
- PET/CT
- Positron emission tomography / computed tomography
- PH
- Pulmonary Hypertension
- RA
- Right Atrium
- RAP
- Right Atrial Pressure
- RV
- Right Ventricle
- RVED
- Right Ventricle End-Diastolic
- RVES
- Right Ventricle End-Systolic
- RVSP
- Right Ventricle Systolic Pressure
- SUV
- Standardized Uptake Value
- TAPSE
- Tricuspid Annular Plane Systolic Excursion
- TC
- Total Cholesterol
- TG
- Total Triglycerides
- VLDL-C
- Very low-density lipoprotein cholesterol
- WHO
- World Health Organization